News

Agreement enables rapid, efficient and impactful expansion to the primary care physician audience. HLS will continue to focus primarily on specialists while Pfizer will focus primarily on primary...

Q2 2021 revenue of $14.9 million and Adjusted EBITDA of $6.6 million, up 19% and 36%, respectively, from Q2 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2021 financial results on Thursday, August 5, 2021. The Company will hold a conference call that...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...

Q1 2021 revenue of $14.3 million, Adjusted EBITDA of $6.7 million and cash from operations of $7.2 million, up $0.4 million, $0.6 million and $1.8 million, respectively, from Q1 2020 Vascepa...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2021 financial results on Thursday, May 6, 2021. The Company will hold a conference call that same...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...

HLS Therapeutics Inc. regrets the adoption of a new regulation, published yesterday in the Gazette officielle du Québec, which limits access to a support program for new patients suffering from...

Dorval, le 1er avril 2021. — HLS Therapeutics Inc. déplore l’adoption d’un nouveau règlement, publié hier dans la Gazette officielle du Québec, qui aura des conséquences sur l’accès...

CCS dyslipidemia management guidelines published in the Canadian Journal of Cardiology (CJC) on March 26, 2021 Strong recommendation for the use of icosapent ethyl for Primary Prevention (diabetes...

Fourth quarter revenue of $16.5 million, Adjusted EBITDA of $8.7 million and cash from operations of $5.8 million Produced strong Vascepa® prescription growth amid COVID-19 challenges: more than...

28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%,...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2020 financial results by press release at 6:30 a.m. EST on Thursday, March 18, 2021....

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will participate in...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will be participating...

Private payer health plan coverage in Canada for Vascepa is expected to reach more than 80% by the end of February 2021, up from 50% in November 2020 Coverage effective for statin-treated patients...

Vascepa included in Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology1 Chinese Society of Cardiology updated Guidelines now include...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it intends to redeem the...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that John L. Welborn, Jr.,...

Health Canada approves MyCare Psychiatry Lab Assays for use in diagnostic lab settings to measure blood levels in patients prescribed six of the most common antipsychotic drugs MyCare Insite...

Results presented in Late Breaker session at National Lipid Association Scientific Sessions 2020 Vascepa COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in connection with its...

first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia once-monthly dosing may help improve treatment compliance PERSERIS is a first-line treatment option for...

Results from Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual Scientific Sessions 2020 VASCEPA®, compared with placebo, significantly...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief...

Revenue of $13.1 million, Adjusted EBITDA of $4.5 million and cash from operations of $2.4 million Produced strong Vascepa prescription growth amid COVID-19 challenges: approximately 1,200...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2020 financial results by press release at 6:30 a.m. Eastern Daylight Time on Thursday, November 5,...

In vitro data presented provides additional insight into potential mechanisms by which Vascepa reduces cardiovascular risk TORONTO, Oct. 22, 2020 /CNW/ - "The Vascepa story continues to unfold as...

HLS anticipates the portfolio will generate sustained and diversified revenues and cash flows Portfolio forecasted to generate an IRR in excess of 20% per year for at least ten years Compelling...

U.S. decision does not relate to Vascepa in Canada Vascepa was granted 8 years of data exclusivity by Health Canada upon approval Vascepa patent estate could potentially extend protection in...

Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPA Significant coronary plaque regression of low attenuation plaque (LAP) reported with VASCEPA provides...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, President...

Revenue of $12.6 million and Adjusted EBITDA of $4.8 million Increasing peak-year sales estimate for Vascepa to C$275-325 million Clozaril's Canadian patient count and sales in local currency...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2020 financial results by press release at 6:30 a.m. Eastern Time on Thursday, August 6, 2020. The...

CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. PMPRB notifies HLS that following PMPRB's review, Vascepa's introductory price...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, President...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, confirms that its Annual Meeting of...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, Chief...

The MyCare Insite is a point-of-care (POC) device that uses just a single drop of blood to measure the most commonly used antipsychotic drugs in patients' blood The MyCare Psychiatry Clozapine...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in collaboration with...

Revenue of $13.9 million, Adjusted EBITDA of $6.1 million and Cash from Operations of $5.3 million Launched Vascepa® in the Canadian market Vascepa added to Health Canada's Register of Innovative...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2020 financial results by press release at 6:30 a.m. Eastern Time on Thursday, May 7, 2020. The...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, comments on the United States District...

Revenue of $54.2 million, Adjusted EBITDA of $31.6 million and Cash from Operations of $26.4 million Received approval from Health Canada for Vascepa® to reduce the risk of cardiovascular events...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...

Vascepa to be available on or about February 18, 2020, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada-approved medication for reducing...

If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia TORONTO, Jan. 23, 2020 /CNW/ - HLS Therapeutics...

Peak-year sales estimate increases to CAD$200-300 million, from CAD$150-250 million Commercial launch expected to take place in the mid-February 2020 timeframe Vascepa is the subject of numerous...

Health Canada approval follows priority review for Vascepa Vascepa becomes the first and only HC-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that the Endocrinologic and...

Revenue of $13.4 million, Adjusted EBITDA of $8.0 million and Cash from Operations of $6.8 million Paid a quarterly dividend of C$0.05 per outstanding common share Subsequent to quarter-end,...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...

From a single drop of blood from the tip of a finger, Athelas One WBC System generates white blood cell counts and neutrophils percentages in minutes The device could help lower the most commonly...

À partir d'une seule goutte de sang du bout d'un doigt, le système d'analyses Athelas One fournit la numération des globules blancs et le pourcentage de neutrophiles en quelques minutes. Le...

Revenue of $13.6 million, Adjusted EBITDA of $8.1 million and Cash from Operations of $9.0 million Filed the New Drug Submission for Vascepa® with Health Canada after having been granted Priority...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held on June 21, 2019 in Toronto, Ontario. A total of 23,983,572 Common...

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, June 5, 2019...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will present at the...

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ ETOBICOKE, ON, May 14,...

Revenue of $13.2 million, Adjusted EBITDA of $8.3 million and Cash from Operations of $8.3 million Granted priority review status for Vascepa™ by Health Canada, which could reduce the review...

Cardiovascular disease is the leading cause of death globally1 NDS for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center cardiovascular outcomes study that...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, CEO, will...

Cardiovascular disease is the leading cause of death globally1 HLS New Drug Submission (NDS) for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center...

Revenue of $61.4 million, Adjusted EBITDA of $41.1 million and Cash from Operations of $32.7 million for the year-ended December 31, 2018 REDUCE-IT™ cardiovascular outcomes study of Vascepa®,...

Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa Usage Grow Over Time TORONTO, March 19, 2019 /CNW/ - HLS Therapeutics...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that on March 16, 2019, Amarin...

From a single drop of blood from the tip of a finger, the point-of-care technology generates white blood cell counts and neutrophils numbers in minutes When approved in Canada, the Athelas One...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, the...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, is pleased to announce that it...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it has received...

REDUCE-IT™ cardiovascular outcomes study of Vascepa®, for which HLS has in-licensed exclusive Canadian rights, exceeded primary endpoint demonstrating an approximately 25% relative risk...

Cardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks Reduced by 31% Fatal or Nonfatal Stroke Reduced by 28% Urgent or Emergent Coronary Revascularization Reduced by 35%...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its third quarter...

REDUCE-IT is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors Results Specific...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has...

Revenue of $16.3 million, Net Loss of $0.6 million and Adjusted EBITDA of $11.0 million, which were all in line with expectations Debt refinancing co-led by JPMorgan Chase Bank, N.A. and Silicon...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its second quarter...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces voting results for the election of directors at its Annual Meeting of Shareholders held on June 22, 2018 in Toronto, Ontario. A...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces details of its upcoming Annual Meeting of Shareholders. Date: Friday June 22, 2018 Time: 10:00 a.m. ET Location: Blake, Cassels...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that it has entered into an automatic share purchase plan (the "ASPP") with a designated broker in order to facilitate...

Commenced trading on the TSX Venture Exchange (Toronto Stock Exchange) Revenue of $13.2M in Q1 2018 vs $15.6M in Q1 2017. Clozaril generates year-over-year growth; Absorica royalties reflect...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that the TSX Venture Exchange ("TSXV") has approved the Company's Notice of Intention to Make a Normal Course Issuer Bid...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its first quarter...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that Mr. Ryan C. Lennox has been named...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that it intends to redeem 9,321,492 (71.83%) of the Company's outstanding Class A preferred shares ("Preferred Shares") on May...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), an emerging specialty pharmaceutical company, announces that Greg Gubitz, CEO, will present at the Bloom Burton & Co. Healthcare...

Revenue was $75.1 million, a 39% increase year-over-year Cash generated from operations was $27.2 million, a 25% increase year-over-year Reverse Take-Over and listing on TSX-V completed post year end

HLS Therapeutics Inc. (TSXV: HLS) today announced that it will release its fourth quarter 2017 financial results by press release on Thursday, March 29, 2018, prior to market open. The Company...

Bill Wells, Executive Chairman of the Board, HLS Therapeutics Inc. (HLS), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market. HLS Therapeutics Inc. is a...

HLS Expected to Begin Trading on the TSXV on March 14, 2018 /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION...

TORONTO, ONTARIO and PICKERING, ONTARIO--(Marketwired - Dec. 21, 2017) - THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO...